IDYA
Neutral signalScored 2026-10-09 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
IDEAYA Biosciences, Inc.
- Nom
- IDEAYA Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.4B
- Employés
- 145
- PDG
- Yujiro S. Hata
- Site web
- https://www.ideayabio.com
- Marché
- COGTERASFHTXNRIXPRLDRVMD
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 26 338 titres (~984 696,17 $ US)
- Insiders
- Hata Yujiro S
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$30,610
Avg sell (VWAP, 90d window) $38.26 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$30,610 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-06
- Last synced
-
2026-10-12 10:13:32
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S | Sell · S · 10b5-1 | 800 | $38.26 | $30,610 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-09 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
IDYA presents a structurally weak profile: despite solid near-term liquidity (score 85), the deeply negative fundamentals trend (score 35) and minimal catalyst score (25) reflect a pre-revenue biotech burning cash with…
The first sentence of the analysis written for IDYA on 2026-10-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $31K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $31K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 11.34 · operating margin -73% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -43.9% | 45.2% | 82.9% | 95.9% | 93.8% | |
| Ebit Margin | -72.8% | -3921.1% | -483.0% | -115.2% | -178.1% | |
| Ebitda Margin | -70.7% | -3866.3% | -465.9% | -111.0% | -171.9% | |
| Operating Profit Margin | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | |
| Pretax Profit Margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | |
| Continuous Operations Profit Margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | |
| Net Profit Margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | |
| Bottom Line Profit Margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | |
| Current Ratio | 11.336 | 14.971 | 19.654 | 11.680 | 5.558 | |
| Quick Ratio | 11.336 | 14.971 | 19.654 | 11.680 | 5.558 | |
| Solvency Ratio | -1.263 | -4.167 | -3.860 | -1.468 | -0.602 | |
| Cash Ratio | 1.918 | 1.831 | 5.794 | 2.164 | 2.038 | |
| Price To Earnings Ratio | -27.008 | -7.649 | -18.153 | -12.796 | -16.766 | |
| Price To Earnings Growth Ratio | 0.436 | -0.107 | -0.477 | -18.042 | -2.196 | |
| Forward Price To Earnings Growth Ratio | 0.436 | -0.107 | -0.477 | -18.042 | -2.196 | |
| Price To Earnings Diluted Ratio | -27.008 | -7.649 | -18.153 | -12.796 | -16.766 | |
| Price To Earnings Diluted Growth Ratio | 0.436 | -0.107 | -0.477 | -18.042 | -2.196 | |
| Price To Book Ratio | 2.990 | 1.982 | 3.295 | 2.155 | 2.764 | |
| Price To Sales Ratio | 13.986 | 299.875 | 87.516 | 14.786 | 29.826 | |
| Price To Free Cash Flow Ratio | -41.637 | -8.348 | -17.404 | -8.310 | -14.264 | |
| Price To Operating Cash Flow Ratio | -43.024 | -8.478 | -17.762 | -8.638 | -14.941 | |
| Debt To Assets Ratio | 0.025 | 0.017 | 0.004 | 0.009 | 0.014 | |
| Debt To Equity Ratio | 0.027 | 0.018 | 0.005 | 0.010 | 0.017 | |
| Debt To Capital Ratio | 0.027 | 0.018 | 0.005 | 0.010 | 0.017 | |
| Long Term Debt To Capital Ratio | 0.026 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.084 | 1.061 | 1.045 | 1.110 | 1.265 | |
| Working Capital Turnover Ratio | 0.350 | 0.012 | 0.055 | 0.187 | 0.123 | |
| Operating Cash Flow Ratio | -1.209 | -5.374 | -4.252 | -2.748 | -1.235 | |
| Operating Cash Flow Sales Ratio | -0.325 | -35.369 | -4.927 | -1.712 | -1.996 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.033 | 1.016 | 1.021 | 1.039 | 1.047 | |
| Debt Service Coverage Ratio | -456.401 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -209.729 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.547 | -12.915 | -40.120 | -25.036 | -10.766 | |
| Capital Expenditure Coverage Ratio | -30.024 | -64.191 | -48.659 | -25.319 | -21.096 | |
| Dividend Paid And Capex Coverage Ratio | -30.024 | -64.191 | -48.659 | -25.319 | -21.096 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -19.222 | -7.515 | -17.369 | -12.164 | -15.540 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -43.9% | ▼-89.1% | ▼-98.7% |
| Ebit Margin | -72.8% | ▲3848.3% | ▲881.2% |
| Ebitda Margin | -70.7% | ▲3795.6% | ▲866.5% |
| Operating Profit Margin | -72.8% | ▲4598.2% | ▲1051.4% |
| Pretax Profit Margin | -52.0% | ▲3869.1% | ▲897.9% |
| Continuous Operations Profit Margin | -52.0% | ▲3869.1% | ▲897.9% |
| Net Profit Margin | -52.0% | ▲3869.1% | ▲897.9% |
| Bottom Line Profit Margin | -52.0% | ▲3869.1% | ▲897.9% |
| Current Ratio | 11.336 | ▼-3.635 | ▼-1.304 |
| Quick Ratio | 11.336 | ▼-3.635 | ▼-1.304 |
| Solvency Ratio | -1.263 | ▲2.904 | ▲1.009 |
| Cash Ratio | 1.918 | ▲0.087 | ▼-0.831 |
| Price To Earnings Ratio | -27.008 | ▼-19.359 | ▼-10.534 |
| Price To Earnings Growth Ratio | 0.436 | ▲0.543 | ▲4.514 |
| Forward Price To Earnings Growth Ratio | 0.436 | ▲0.543 | ▲4.514 |
| Price To Earnings Diluted Ratio | -27.008 | ▼-19.359 | ▼-10.534 |
| Price To Earnings Diluted Growth Ratio | 0.436 | ▲0.543 | ▲4.514 |
| Price To Book Ratio | 2.990 | ▲1.008 | ▲0.353 |
| Price To Sales Ratio | 13.986 | ▼-285.889 | ▼-75.212 |
| Price To Free Cash Flow Ratio | -41.637 | ▼-33.289 | ▼-23.645 |
| Price To Operating Cash Flow Ratio | -43.024 | ▼-34.546 | ▼-24.456 |
| Debt To Assets Ratio | 0.025 | ▲0.008 | ▲0.011 |
| Debt To Equity Ratio | 0.027 | ▲0.009 | ▲0.012 |
| Debt To Capital Ratio | 0.027 | ▲0.009 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.026 | ▲0.026 | ▲0.021 |
| Financial Leverage Ratio | 1.085 | ▲0.023 | ▼-0.029 |
| Working Capital Turnover Ratio | 0.349 | ▲0.337 | ▲0.204 |
| Operating Cash Flow Ratio | -1.209 | ▲4.165 | ▲1.755 |
| Operating Cash Flow Sales Ratio | -0.325 | ▲35.044 | ▲8.541 |
| Free Cash Flow Operating Cash Flow Ratio | 1.033 | ▲0.018 | ▲0.002 |
| Debt Service Coverage Ratio | -456.401 | ▼-456.401 | ▼-365.121 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -209.729 | ▼-209.729 | ▼-167.783 |
| Operating Cash Flow Coverage Ratio | -2.547 | ▲10.367 | ▲15.730 |
| Capital Expenditure Coverage Ratio | -30.024 | ▲34.166 | ▲7.833 |
| Dividend Paid And Capex Coverage Ratio | -30.024 | ▲34.166 | ▲7.833 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -19.222 | ▼-11.707 | ▼-4.860 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.06B | $2.10B | $2.05B | $753.1M | $833.4M | |
| Enterprise value | $2.97B | $2.03B | $1.89B | $687.9M | $746.5M | |
| EV / Sales | 13.60x | 290.56x | 80.92x | 13.51x | 26.72x | |
| EV / Op. cash flow | -41.83x | -8.21x | -16.42x | -7.89x | -13.38x | |
| EV / Free cash flow | -40.48x | -8.09x | -16.09x | -7.59x | -12.78x | |
| EV / EBITDA | -19.22x | -7.51x | -17.37x | -12.16x | -15.54x | |
| Net debt / EBITDA | 0.55x | 0.24x | 1.42x | 1.15x | 1.81x | |
| Current ratio | 11.34x | 14.97x | 19.65x | 11.68x | 5.56x | |
| Income quality | 0.62x | 0.90x | 1.02x | 1.49x | 1.12x | |
| Graham net-net | $6 | $7 | $9 | $8 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 71.4% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $607.9M | $643.6M | $505.5M | $338.7M | $205.8M | |
| Invested capital | $639.2M | $671.4M | $513.9M | $347.7M | $214.5M | |
| Return on assets | -10.2% | -24.4% | -17.4% | -15.1% | -13.0% | |
| Operating ROA | -14.3% | -36.9% | -25.9% | -16.2% | -14.8% | |
| Return on tangible assets | -10.2% | -24.4% | -17.4% | -15.1% | -13.0% | |
| Return on equity | -11.1% | -25.9% | -18.2% | -16.8% | -16.5% | |
| Return on invested capital | -15.2% | -30.3% | -21.5% | -17.5% | -14.9% | |
| Return on capital employed | -15.2% | -30.3% | -21.6% | -17.5% | -15.0% | |
| Earnings yield | -3.7% | -13.1% | -5.5% | -7.8% | -6.0% | |
| Free cash flow yield | -2.4% | -12.0% | -5.7% | -12.0% | -7.0% | |
| Capex / Op. cash flow | -3.3% | -1.6% | -2.1% | -3.9% | -4.7% | |
| Capex / Depreciation | 51.6% | 100.6% | 59.1% | 163.9% | 153.3% | |
| Capex / Sales | 1.1% | 55.1% | 10.1% | 6.8% | 9.5% | |
| SG&A / Sales | 29.0% | 506.7% | 103.9% | 42.8% | 65.6% | |
| R&D / Sales | 143.9% | 4209.6% | 553.8% | 175.8% | 208.1% | |
| Stock comp / Sales | 21.1% | 496.4% | 79.1% | 22.8% | 29.5% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 10d | 0d | 0d | 2d | 14d | |
| Days payables outstanding | 20d | 1468d | 601d | 744d | 444d | |
| Operating cycle | 10d | 0d | 0d | 2d | 14d | |
| Cash conversion cycle | -10d | -1468d | -601d | -742d | -430d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-11 IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer owned 690,695 shares of the
- 2026-09-30 IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)''s stock price traded up 4.8% on Monday. The company traded as high as $38.38 and last traded at $38.45. Approximately 278,808 shares traded hands during trading, a decline of 73% from the average session volume of 1,041,522 shares. The stock had previously closed at $36.69. Analyst Upgrades
- 2026-09-28 IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.
- 2026-09-25 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA''s Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company''s common stock to three newly hired employees.
- 2026-09-18 Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,218 shares of the company''s stock after selling 74,060 shares during the period. Squarepoint Ops LLC''s holdings in IDEAYA
- 2026-09-10 IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-09 IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of darovasertib across the uveal melanoma patient journey into the adjuvant setting, where there is a significant unmet need for systemic treatment options designed to reduce the risk of metastatic recurrence SOUTH SAN FRANCISCO, Calif., Sept. 9, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed local therapy and have an increased risk of developing metastatic disease.
- 2026-09-01 IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
- 2026-08-31 IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval and median OS as the primary endpoint for potential full approval Dose evaluation ongoing of 2.4mg/kg and 3.5 mg/kg IV Q3W to determine the RP3D Target enrollment for the Phase 3 study will be ~400 ES-SCLC patients, randomized 1:1 treatment vs. investigator''s choice Clinical data updates for IDE849 in 100 ES-SCLC and NEC patients by partner Hengrui at ESMO 2026 and the IDEAYA sponsored Phase 1/2 clinical trial in ES-SCLC and NEC in Q4 2026 to support a potential best-in-class profile IDE849 is being evaluated in clinical combinations with PDL1 and IDEAYA''s PARG inhibitor IDE161 to determine a potential 1L SCLC Phase 3 registrational trial design SOUTH SAN FRANCISCO, Calif.
- 2026-08-28 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISC